SERINC1 (serine incorporator 1) is a multipass transmembrane protein that enhances the incorporation of serine into phosphatidylserine and sphingolipids 1. As a member of the SERINC protein family, SERINC1 localizes to the endoplasmic reticulum and plasma membrane, functioning in membrane biogenesis and lipid metabolism 2. The protein is subject to complex regulation, including estrogen-responsive transcriptional control in breast cancer cells 3. Regarding disease relevance, SERINC1 expression correlates with clinical outcomes in multiple malignancies. In colorectal cancer peritoneal metastasis, SERINC1 was identified as a driver gene, with functional studies demonstrating that SERINC1 knockdown suppresses peritoneal dissemination 4. In pituitary adenomas, SERINC1 expression correlates with tumor volume changes following somatostatin analog treatment 5. Additionally, genome-wide Mendelian randomization analysis identified SERINC1 as a genetic susceptibility target for unruptured intracranial aneurysms 6. While SERINC1 lacks the potent antiviral restriction activity demonstrated by SERINC3 and SERINC5 against HIV and hepatitis B 71, its roles in lipid metabolism and tumor progression suggest therapeutic potential. Further investigation of SERINC1's mechanistic functions in cancer metastasis and aneurysm development is warranted.